Astrazeneca Share News (AZN)
AZN Share
AZN Share
AZN Share
AZN Share
AZN
AZN Share
AZN Level 2
AZN Live
AZN Broker
AZN Directors
AZN Financial
AZN
AZN Short
AZN
Last checked at -
(Alliance News) - AstraZeneca PLC on Wednesday announced that eculizumab, whose brand name is Solaris, has been approved in China to treat patients with neuromyelitis optica spectrum disorder
Read more(Alliance News) - London's FTSE 100 higher was higher around midday, though it was defensive stocks such as utilities and pharmaceuticals which led the charge, suggesting there is still lingering discomfort in markets amid tensions in the Middle East.
Read more(Alliance News) - AstraZeneca PLC on Monday said that its new drug application for Tagrisso has been granted priority review in the US, after trial results extended progression-free survival.
Read moreAstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows "clinically meaningful" improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes.
Read more(Alliance News) - Stocks in London were lower at the close on Tuesday after unexpectedly strong US job openings data added to fears that interest rates in the world's largest economy will stay higher for longer.
Read more(Alliance News) - London's FTSE 100 grew in confidence as Tuesday morning progressed, going into the afternoon in the green and outperforming European peers.
Read more(Alliance News) - AstraZeneca PLC on Tuesday said it has settled legal matters involving its Nexium acid reflux and Prilosec heartburn products, parting with USD425 million.
Read more(Alliance News) - London's FTSE 100 is set to fall further on Tuesday, after a sell-off at the start of the week, with hawkish words from a US central banker reinforcing the 'higher-for-longer' interest rates messaging.
Read more
(Sharecast News) - Global pharmaceutical company AstraZeneca has agreed to settle litigation on product liability related to two of its widely-used heartburn drugs, Nexium and Prilosec, it announced on Tuesday.
Read more(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:
Read more(Alliance News) - Stocks in London were set to open lower on Monday as investors eyed fresh concerns for the already fragile Chinese property sector.
Read more(Alliance News) - Stock prices in London opened lower on Friday, but managed to avoid the steep declines seen in New York, as investors mulled over an eventful week dominated by central bank decisions.
Read more(Alliance News) - AstraZeneca PLC on Friday said phase three data showed that datopotamab deruxtecan delivered improvement in progression-free survival in breast cancer patients.
Read more(Sharecast News) - New high-level results from AstraZeneca's TROPION-Breast01 phase three trial, released on Friday, carried encouraging news for patients with inoperable or metastatic hormone receptor (HR)-positive, HER2-low or negative breast cancer.
Read more(Alliance News) - AstraZeneca PLC on Wednesday said rare disease business Alexion has signed a purchase and licence agreement for a rare disease programme portfolio from Pfizer Inc.
Read more
Last checked at